Abstract
Vascular calcification is an important risk factor associated with mortality among patients with chronic kidney disease. Intracellular cholesterol metabolism is involved in the process of vascular cell calcification. In this study, we investigated the role of UbiA prenyltransferase domain containing 1 (UBIAD1) in intracellular cholesterol metabolism and vascular cell calcification, and identified its subcellular location. Primary human umbilical vein smooth muscle cells (HUVSMCs) were incubated with either growth medium (1.4 mmol/L Pi) or calcification medium (CM) (3.0 mmol/L Pi). Under treatment with CM, HUVSMCs were further incubated with exogenous cholesterol, or menaquinone-4, a product of UBIAD1. The plasmid and small interfering RNA were transfected in HUVSMCs to alter the expression of UBIAD1. Matrix calcium quantitation, alkaline phosphatase activity, intracellular cholesterol level and menaquinone-4 level were measured. The expression of several genes involved in cholesterol metabolism were analyzed. Using an anti-UBIAD1 antibody, an endoplasmic reticulum marker and a Golgi marker, the subcellular location of UBIAD1 in HUVSMCs was analyzed. CM increased matrix calcium, alkaline phosphatase activity and intracellular cholesterol level, and reduced UBIAD1 expression and menaquinone-4 level. Addition of cholesterol contributed to increased matrix calcification and alkaline phosphatase activity in a dose-dependent manner. Elevated expression of UBIAD1 or menaquinone-4 in HUVSMCs treated with CM significantly reduced intracellular cholesterol level, matrix calcification and alkaline phosphatase activity, but increased menaquinone-4 level. Elevated expression of UBIAD1 or menaquinone-4 reduced the gene expression of sterol regulatory element-binding protein-2, and increased gene expression of ATP binding cassette transporters A1, which are in charge of cholesterol synthesis and efflux. UBIAD1 co-localized with the endoplasmic reticulum marker and the Golgi marker in HUVSMCs. In conclusion, high intracellular cholesterol content contributes to phosphate-induced vascular cell differentiation and calcification. UBIAD1 or menaquinone-4 could decrease vascular cell differentiation and calcification, probably via its potent role of inversely modulating cellular cholesterol.
Highlights
Vascular calcification (VC) is prevalent among patients with chronic kidney disease and is associated with increased risk of cardiovascular morbidity and mortality [1,2,3,4,5]
We investigated the role of UbiA prenyltransferase domain containing 1 (UBIAD1) in intracellular cholesterol metabolism and vascular smooth muscle cells (VSMCs) calcification and osteogenic differentiation induced by high phosphate, as well as the subcellular location of UBIAD1 in VSMCs
human umbilical vein smooth muscle cells (HUVSMCs) treated with calcification medium (CM) showed increased intracellular cholesterol level (Fig 1C)
Summary
Vascular calcification (VC) is prevalent among patients with chronic kidney disease and is associated with increased risk of cardiovascular morbidity and mortality [1,2,3,4,5]. One key event involved in VC promotion is an increase in extracellular calcium and phosphate, which leads to the transition of VSMCs from a contractile to an osteo-chondrogenic phenotype with the formation of a pro-calcifying matrix and vesicles able to nucleate hydroxyapatite. This process is associated with the loss of mineralization inhibitors, including matrix gla protein and pyrophosphate, calcium- and phosphate-dependent cell death, the production of apoptotic bodies, and the development of mineral nucleation [6,7]. In classic highphosphate induced VC, the role of intracellular cholesterol metabolism remains unknown
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have